中国疫苗行业协会：坚决抵制无序低价竞争 严禁以低于成本的报价参与竞标

Core Viewpoint - The China Vaccine Industry Association has issued an initiative to oppose "involution-style" competition and promote high-quality development in the vaccine and related biological products industry, emphasizing the need for self-discipline and innovation to create a healthy and orderly competitive environment [1][2]. Group 1: Regulatory Compliance - All members of the China Vaccine Industry Association must strictly adhere to the Vaccine Administration Law and the Price Law of the People's Republic of China, as well as industry self-discipline conventions [2]. - Members are required to base pricing on production costs and market supply-demand conditions, ensuring fair and legal pricing practices [2]. Group 2: Competition and Pricing - The initiative calls for a firm resistance against disorderly low-price competition, prohibiting bids below cost throughout the tendering process to ensure product and service quality standards [1][2]. - Members are encouraged to maintain market price stability and foster a fair and orderly competitive environment [1]. Group 3: Innovation and Development - The association emphasizes the importance of innovation-driven development, urging members to focus on key core technology breakthroughs and the research and application of innovative products [2]. - The initiative aims to promote high-quality development in the vaccine and related biological products industry through a healthy and fair competitive environment [2].